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Abstract 
Change of CD20 expression was examined in cases of diffuse large B-cell lymphoma 
(DLBCL). CD20 expression after treatment with anti-CD20 antibody (rituximab, Rx) for 
DLBCL was examined in 23 cases who received serial biopsy by immunohistochemistry 
(IHC) and flow cytometry (FCM). CD20– by IHC and/or FCM was defined as CD20–. Four 
cases were CD20– at initial biopsy but became CD20+ after chemotherapy with Rx (CH-R) 
(group A). Recurrent tumors in three group A cases became resistant to CH-R. Initial and 
recurrent tumors were CD20+ before and after CH-R in 17 cases (group B). Tumors before 
CH-R were CD20– in two cases (group C) and continued to be CD20– in one and turned 
CD20+ in the other with survival time after the relapse of 8 and 23 months, respectively. 
Evaluation of CD20 expression with immunohistochemical and flow cytometric methods 
is used for the prediction of responsiveness of relapsed DLBCL for CH-R. 
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Introduction 
CD20, a hydrophobic transmembrane protein with a molecular weight of 
approximately 35 kD, is expressed on pre B and mature B lymphocytes [1] and B-cell 
lymphoma. Rituximab (Rx) is a chimeric anti-human CD20 antibody, and approved for 
the use in treatment of B-cell lymphomas [2] and immune-related diseases such as 
rheumatoid arthritis [3]. Action mechanisms of Rx for elimination of nonneoplastic and 
neoplastic B cells include complement-dependent cytotoxicity, antibody-dependent 
cellular cytotoxicity, and stimulation of apoptotic pathway [2]. Rx was originally 
employed for the treatment of low-grade or follicular lymphoma. Later combined use of 
Rx with conventional chemotherapy (cyclophosphamide, doxorubicin, vincristine and 
prednisone) (R-CHOP) was found to be effective for more aggressive diffuse large B-cell 
lymphoma (DLBCL) [4]. DLBCL, the most common category, is defined as a diffuse 
proliferation of large B-lymphoid cells. 
R-CHOP is now employed as a standard therapy for DLBCL, but recurrence of disease 
is not infrequently encountered. In such cases, histologic examination of relapsed tumors 
is usually not performed because the DLBCL does not further transform to more 
aggressive lymphoma or become lower-grade one. To know whether relapsed DLBCL 
continues to express CD20 is essential for the decision of continuous administration of 
Rx, but information for this is quite limited at present. 
In this study, change of CD20 expression in DLBCL after chemotherapy with Rx 
(CH-R) was studied. Histopathologic findings, expression of CD20 in tumor cells as 
revealed by immunohistochemistry (IHC) and flow cytometry (FCM), and identification 
of clone of cells before and after CH-R were evaluated and compared. Clinical relevance 
of loss of CD20 expression in DLBCL is discussed. 
Patients 
From November 1999 to October 2008, a total of 3,902 cases of lymphoproliferative diseases were 
registered with the Osaka Lymphoma Study Group, Osaka, Japan. Histologic specimens obtained by 
biopsy were fixed in 10% formalin and routinely processed for paraffin embedding. Histologic sections, 
cut at 4 μm, were stained with hematoxylin and eosin and immunoperoxidase procedure (ABC 
method). All of the histologic sections were classified according to the WHO classification by one of the 
authors (K.A.). Brief clinical findings were available in all cases. A diagnosis of malignant lymphoma 
was confirmed in 3,115 of 3,902 cases (79.8%). The number of DLBCL cases was 1,382, which 
comprised 44.4% of all lymphomas. Of these 1,382 DLBCL cases, histologic examinations for relapsed 
tumors after administration of chemotherapeutic regimens including Rx were performed in 23 (1.7%) 
cases; these cases constituted the basis of the present study. This study was approved by the institutional 
research board of Osaka University Graduate School of Medicine. Clinical information available in the 
23 patients included age, sex, primary site, stage, international prognostic index, response to Rx 
treatment, and follow-up. The follow-up period for the survivors ranged from 8.6 to 93.6 (median 50.2) 
months. 
Immunohistochemical and Flow Cytometric Analyses 
Monoclonal antibodies used for IHC were CD20, CD79a, and CD3 (DakoCytomation, Glostrup, 
Denmark, dilution at 1:400, 1:100 and 1:50, respectively). CD79a expression was essential for the 
diagnosis of B-cell lymphoma in cases not expressing CD20. IHC revealed that the cases expressing 
CD20 were clearly divided into two groups: almost all cells expressed CD20 in one group (CD20+ cases) 
and less than 10% cells did in the other (CD20– cases). Flow cytometric analysis was performed with 
Becton Dickinson laser flow cytometer (FACS Calibur) by three-color analysis technique. Gating was 
done using forward and side scatter criteria. Cases with labeling of more than 20% of the large lymphoid  
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cells were judged as CD20+ or CD19+. When the percentage of CD20 labeling cells was less than 20%, 
positivity for CD19 was a requisite for CD20– DLBCL. According to the criteria used by Kennedy et al. 
[5], cases showing CD20 negativity by IHC and/or FCM were defined as CD20– in this study. 
Clonality Analysis with Use of Immunoglobulin Gene Rearrangement (GeneScan 
Analysis) 
DNA was extracted from the paraffin-embedded samples with phenol-chloroform extraction-based 
protocol, followed by ethanol precipitation and redissolved in TE buffer. Immunoglobulin (Ig) gene 
rearrangement was assessed by eight PCRs with 41 primers according to BIOMED-2 protocols [6]. For 
this, fluorescence-labeled (6-FAM, VIC, NED, PET) custom-made primers were purchased from 
Applied Biosystems (Tokyo, Japan). The amplified PCR products with internal size standard 
(GeneScan-600 LIZ, Applied Biosystems) were analyzed using ABI PRISM 310 genetic analyzer with 
DS-33 dye-set and software v.3.1. (Applied Biosystems). Samples for clonality analysis before and after 
CH-R were not available in 12 cases. 
Results 
Change of CD20 expression pattern in the initial and recurrent tumors is summarized 
in table 1. Tumors in four (19%) of 21 cases which were CD20+ at initial biopsy became 
CD20– after CH-R (group A) (fig. 1). In the remaining 17 cases, tumor cells remained 
CD20+ in the recurrent lesions (group B). Tumors in another two cases were CD20– by 
FCM but CD20+ by IHC before CH-R, thus judged CD20– (group C): they continued to 
be CD20– by FCM but CD20+ by IHC in one and turned to be CD20+ by FCM in the 
other. Clinical findings in the four group A cases are summarized in table 2. The interval 
between the last administration of Rx and CD20– relapse in group A cases ranged from 1 
to 12 (mean 4.5) months. The remaining 19 cases in groups B and C (group non-A) 
comprised 11 males and 8 females with a median age of 63 years. The primary site was 
lymph node in 3 cases, skin in 2, testis in 2, one each of breast, colon, popliteal region, 
prostate, stomach, thyroid gland, and tonsil, and unknown in 5. Stage was I in one case, II 
in 7, III in 2, and IV in 9. 
There were no prominent differences in histologic features of DLBCL between group A 
and non-A cases before and after CH-R. Mean mitotic counts before CH-R at 10 
high-power fields ranged from 2.0 to 4.5 (median 2.6) and from 1.0 to 7.5 (median 2.1) in 
group A and non-A cases, respectively, and those after CH-R ranged from 2.3 to 5.3 
(median 4.4) and from 1.0 to 8.5 (median 3.3) in group A and non-A cases, respectively. 
Mitotic counts in the recurrent tumors were higher than those in the initial tumors in 
both group A and non-A cases. 
The mode of Rx administration was as follows: all patients received Rx with 375 mg/m
2 
per one dose, and total doses until last relapse ranged from 3 to 14 (mean 9) and from 2 to 
20 (mean 6.3) doses in group A and non-A cases, respectively. The interval between the 
first Rx medication and last relapse ranged from 2.3 to 25.7 (mean 14.1) months and from 
2.6 to 63.1 (mean 22.0) in group A and non-A cases, respectively. 
Rx administration was stopped when CD20 turned to be negative by IHC in the 
recurrent tumors in cases 1, 2 and 3. CD20 became negative by FCM but persistently 
positive by IHC in case 4. Rx administration was continued in case 4, but the patient 
showed progressive disease four months after CD20 negativity by FCM. The remaining 
two group A cases (cases 1 and 3) became resistant to CH-R at relapse. In case 2, Rx was 
not employed for the relapsed lesion, thus response of the relapsed tumor to Rx was 
unknown. 5 of 13 group B and 2 of 2 group C patients became resistant to CH-R at  
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relapse. Information for response for Rx administration at relapse was not available in 
four group B cases. 
Peak patterns in the GeneScan analysis before and after CH-R were compared in the 2 
of 4 group A, 7 of 17 group B, and 2 of 2 group C cases (table 1). All of the group A, B and 
C cases showed peaks before and after CH-R, indicating monoclonality for Ig genes with 
at least one primer (fig. 2). All of these cases showed partial or complete persistence of the 
same sized peaks before and after CH-R, indicating the same origin of tumor cells. 
Discussion 
Information for CD20 expression in DLBCL after CH-R is quite limited at present. 
When the criteria for CD20 negativity employed in the previous study was applied in this 
study [5], 4 (19%) of the present 21 cases changed from CD20+ before CH-R to CD20– 
after CH-R. This frequency was significantly lower than that reported by Kennedy et al. 
from Australia [5], i.e., 6 of 10 cases (p < 0.05). The mean administrated dose of Rx until 
CD20– relapse in Kennedy et al.’s cases (5 doses) was lower than that of our cases 
(9 doses), but the difference was not significant. The mean interval between the last 
administration of Rx and CD20– relapse in the Kennedy et al.’s cases (5.3 months) was 
relatively close to that in our cases (4.5 months). At present, factors influencing the 
CD20– relapse of DLBCL are unknown. 
The recurrent DLBCL in one of the group A cases showed CD20 negativity by FCM 
but positivity by IHC. A similar phenomenon was observed in one of Kennedy et al.’s 
cases [5]. Those two cases showed progressive disease under Rx treatment. Therefore 
CD20 negativity by FCM also might be a sign for resistance to Rx treatment. FCM and 
IHC analyses detect the different epitopes of CD20: extracellular surface epitopes by FCM 
and intracytoplasmic ones by IHC. Mutation or deletion of genes encoding the surface 
epitopes with preserved intracytoplasmic ones or mask of the surface epitopes by binding 
of CD20 molecules might occur in these cases. There seem to be no prominent differences 
in clinical findings including age, sex, primary site of tumors, and mode of chemotherapy 
between group A and non-A cases. 
GeneScan analysis revealed partial or complete persistence of the same sized peaks in 
all cases, indicating the same origin of tumor cells before and after CH-R. However 
change a in peak pattern was found in 2 of 2 group A, 6 of 7 group B and 1 of 2 group C 
cases, respectively, suggesting the presence of genetic instability. These findings might 
partly explain the occurrence of CD20– DLBCL after CH-R. 
Complete remission and overall response rate of relapsed DLBCL for Rx treatment 
were reported to be 8 and 33%, respectively, and the response rate of recurrent tumors for 
Rx treatment was reported to be significantly lower in DLBCL formerly treated with Rx 
than that not treated with Rx [7]. In group B cases in whom tumors continued to be 
CD20+, the response rate of the relapsed tumors for CH-R was 62% (8 of 13 cases). 
Generally relapsed tumors after CH-R occasionally become resistant to the same 
regimens, but negativity of CD20 is a robust sign for resistance to CH-R. Therefore CD20 
negativity in recurrent DLBCL might partly explain the low response rate for CH-R and 
poor prognosis. Indeed, 3 of 3 group A patients became resistant to CH-R at relapse, and 
2 of them showed disease progression and died. 
Before CH-R, tumors in two group C cases were CD20– by FCM. One of the two cases 
remained CD20– by FCM at relapse, but the other became CD20+. The former case first  
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showed complete remission, but finally died of disease 8 months after relapse. The latter 
case repeated the remission and relapse and was treated by CH-R at every relapse. This 
patient finally died of disease 23 months after the second relapse (the first relapse after 
CH-R). Taken together, CD20 negativity could be a sign for poor response to CH-R, 
although much more information is necessary to confirm this point. 
In conclusion, evaluation of CD20 expression with immunohistochemical and flow 
cytometric methods is a reliable guide for employment of CH-R for DLBCL. Loss of 
CD20 expression after CH-R was less frequently observed in our cases from Japan than in 
those from Australia. 
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Table 1. Antigen expression pattern and peak pattern of GeneScan analysis before and after Rx 
Before Rx  After Rx    
first biopsy  second biopsy  first biopsy  second biopsy  third biopsy          
Case 
IHC  FCM   IHC  FCM   IHC  FCM   IHC  FCM   IHC  FCM   
Peak pattern of 
GeneScan 
analysis before 
and after Rx 
Group A (4 cases) 
1  CD20+  NA   nd  nd   CD20+ NA   CD20–  NA   nd  nd  change   
                 C D 7 9 a +            
2  CD20+  NA   CD20+  CD20+   CD20– NA   nd  nd   nd  nd  change   
            C D 7 9 a +                   
3 CD20+  CD20+    nd  nd    CD20–  CD20–  nd  nd   nd  nd  NA   
            CD79a+  CD19+               
4 CD20+  CD20+    nd  nd    CD20+  CD20–  nd  nd   nd  nd  NA   
              C D 1 9 +                
Group B (17 cases) 
5–21 CD20+  CD20+*   CD20+  CD20+*  CD20+ CD20+*   CD20+  NA   CD20+  NA   change 6  cases
                           i d e n t i c a l   1   c a s e  
Group C (2 cases) 
22 CD20+  CD20–  nd  nd    CD20+ CD20–  nd  nd   nd  nd  identical   
    CD19+          CD19+               
23 CD20+  NA    CD20+  CD20–   CD20+ CD20+  CD20+  CD20+ nd  nd  change  
         C D 1 9 +                      
Rx = Rituximab; IHC = immunohistochemistry; FCM = flow cytometry; NA = data not available; nd = not done.  
*
 Data were available in part of the cases. 
 
 
Table 2. Summary of clinical findings in group A patients 
Case   Age at 
first diag- 
nosis, 
years 
Sex Primary 
site 
Stage IPI Response 
to Rx 
Interval 
between last  
Rx and CD20– 
relapse 
Treatment for  
CD20– relapse 
Follow-up, 
months  
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1 71  F  stomach  II LI  PD  following 
relapse 
4 months  nd  26.0 DT 
2 48  M  LN  III  LI  relapse 
following PR 
12 months  MECP  93.6 A (PR) 
3 72  M  LN  IV  H  PD  following 
relapse 
1 month  ESHAP + Bleo 
VNCOP-B 
12.4 DT 
4 67  M  LN  II L  PD  following 
relapse 
1 month  Rx only 
CHOP-R 
high-dose MTX 
 
8.6 A (PD) 
LN = Lymph node; IPI = international prognostic index; L = low; LI = low-intermediate; H = high; 
PR = partial remission; PD = progressive disease; nd = not done; Bleo = bleomycin; Rx = rituximab; 
MTX = methotrexate; A = alive; DT = death due to tumor; MECP = mitoxantrone, etoposide, carboplatin 
and prednisolone; ESHAP = etoposide, cytarabine, cisplatinum and methylprednisolone; VNCOP-B = 
etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin; CHOP-R = 
cyclophosphamide, doxorubicin, vincristine, prednisolone and rituximab. 
 
 
 
 
Fig. 1. a Initial DLBCL (case 3). H&E. b Tumor cells were CD20+ at IHC. c Recurrent DLBCL after Rx 
treatment showing similar features to the initial DLBCL. H&E. d Recurrent tumor cells were CD20–. 
Inset Tumor cells were CD79a+. All ×400. 
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Fig. 2. Polymerase chain reaction-based clonality analysis for Ig gene rearrangement (GeneScan 
analysis) in case 2 revealed the different peak pattern before and after Rx treatment with partial 
persistence of same sized peaks (Ļ). 
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